CAPRICOR THERAPEUTICS INC. - COMMON STOCK

Capricor Therapeutics to Participate in Upcoming Investor Conferences

10 فبراير 2025 08:00:00 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

02 يناير 2025 08:15:00 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics to Present at Upcoming Investor Conferences

02 ديسمبر 2024 15:15:00 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency

20 نوفمبر 2024 08:00:01 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

13 نوفمبر 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting

12 نوفمبر 2024 08:00:01 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13

05 نوفمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

18 أكتوبر 2024 15:01:00 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock

17 أكتوبر 2024 05:00:00 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

16 أكتوبر 2024 15:17:48 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: CAPRICOR THERAPEUTICS INC. - COMMON STOCK

15 أكتوبر 2024 11:27:21 بحسب NetDania Notify

Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress

11 أكتوبر 2024 08:15:00 بحسب Nasdaq GlobeNewswire

Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

09 أكتوبر 2024 08:15:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: CAPRICOR THERAPEUTICS INC. - COMMON STOCK

04 أكتوبر 2024 08:47:23 بحسب NetDania Notify

Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress

04 أكتوبر 2024 08:15:00 بحسب Nasdaq GlobeNewswire

NetDania - New 12 months High: CAPRICOR THERAPEUTICS INC. - COMMON STOCK

01 أكتوبر 2024 08:48:05 بحسب NetDania Notify

NetDania - New 12 months High: CAPRICOR THERAPEUTICS INC. - COMMON STOCK

30 سبتمبر 2024 10:30:56 بحسب NetDania Notify

NetDania - New 12 months High: CAPRICOR THERAPEUTICS INC. - COMMON STOCK

25 سبتمبر 2024 08:45:14 بحسب NetDania Notify

NetDania - New 12 months High: CAPRICOR THERAPEUTICS INC. - COMMON STOCK

24 سبتمبر 2024 08:45:18 بحسب NetDania Notify

Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

24 سبتمبر 2024 07:00:01 بحسب Nasdaq GlobeNewswire